navoximod

Navoximod (GDC-0919, NLG919) is an orally bioavailable small molecule inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 is a key immunosuppressive enzyme that catalyzes the rate-limiting step of tryptophan degradation into kynurenine. This metabolic pathway creates an immunosuppressive tumor microenvironment by depleting tryptophan (essential for T-cell function) and accumulating toxic metabolites, thereby inhibiting T-cell activity and promoting the differentiation of regulatory T-cells. By inhibiting IDO1, navoximod aims to restore the immune system's ability to recognize and attack tumor cells. Originally developed by NewLink Genetics, it was licensed to Genentech (Roche) in 2014 for development as a monotherapy and in combination with checkpoint inhibitors like atezolizumab. However, following disappointing results across the IDO inhibitor class in the industry, Genentech terminated the collaboration in 2017, and rights to the compound reverted to NewLink Genetics.

Brand names

navoximod

Other names

navoximod